Skin Replacements and Substitutes – Market Insights – United States

The US skin replacements and substitutes market is expected to see gradual revenue growth. This growth will be driven by favorable demographics, increasing procedure volumes in nonhospital settings, and the continued adoption of skin replacements and substitutes for wound healing. However, uncertainties related to upcoming reimbursement systems and regulatory changes may somewhat constrain market expansion.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for skin replacements and substitutes in the US from 2019 through 2032.

Over the past three years there has been a notable increase in the use of nonhospital service locations. 

How do the changes in site of service align with the specific types of wounds treated using skin replacements and substitutes?

How do varying economic incentives at different service sites impact trends in the skin replacement and substitute market?

How are ASPs being affected by this site of service switch?

Modifications in reimbursement policies within the US have impacted compensation for skin replacements and substitutes.

Which different reimbursement systems exist?

How do these reimbursement structures influence procedure volume growth across sites of service?

What strategies are companies employing to secure favorable reimbursement?

The adoption of biologic skin replacement and substitute products is on the rise.

What are the advantages of each biologic product type?

Which manufacturers and brands have been most successful in the biologic space?

What factors determine physician preference for certain biologic skin replacement and substitute products?

Prominent competitive strategies in this domain include product launches, acquisitions, and partnerships.

How have recent major acquisitions within the skin replacement and substitute market affected market shares?

Which segments of the skin replacement and substitute market are experiencing the fastest adoption of new products?

Clinical data play a critical role for physicians when selecting skin replacements and substitutes.

How have clinical trials affected the reimbursement status of key products?

Which companies are investing in clinical trials?

Regulatory updates from the FDA regarding amniotic- and placenta-based products have impacted the competitive landscape.

How have regulatory updates impacted competitors?

How are competitors adjusting their strategies to remain competitive despite regulatory changes?

How have recent product recalls affected or are expected to affect the involved competitors and market trends?